BCI hydrochloride | CAS#95130-23-7 | Dusp6 inhibitor

MedKoo Cat#: 527814 | Name: BCI hydrochloride

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

BCI hydrochloride is an allosteric inhibitor of Dusp6, acting within the phosphatase domain to prevent the catalytic stimulation of phosphatase activity induced by ERK2 substrate binding.

Chemical Structure

BCI hydrochloride

CAS#95130-23-7 (E/Z HCl)

Theoretical Analysis

MedKoo Cat#: 527814

Name: BCI hydrochloride

CAS#: 95130-23-7 (E/Z HCl)

Chemical Formula: C22H24ClNO

Exact Mass: 317.1780

Molecular Weight: 353.89

Elemental Analysis: C22H24ClNO

Price and Availability

Size	Price	Availability	Quantity
10mg	USD 350.00	2 Weeks
50mg	USD 950.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

15982-84-0 (E/Z) 95130-23-7 (E/Z HCl) 1245792-51-1 (E)

Synonym

BCI hydrochloride

IUPAC/Chemical Name

2-Benzylidene-3-(cyclohexylamino)-2,3-dihydro-1H-inden-1-one hydrochloride

InChi Key

JPATUDRDKCLPTI-CRDKNBMZSA-N

InChi Code

InChI=1S/C22H23NO.ClH/c24-22-19-14-8-7-13-18(19)21(23-17-11-5-2-6-12-17)20(22)15-16-9-3-1-4-10-16;/h1,3-4,7-10,13-15,17,21,23H,2,5-6,11-12H2;1H/b20-15-;

SMILES Code

O=C1/C(C(NC2CCCCC2)C3=C1C=CC=C3)=C\C4=CC=CC=C4.[H]Cl

Appearance

Solid powder

Purity

>98% (mixture of isomers)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

BCI hydrochloride is an inhibitor of dual specificity phosphatase (DUSP) with EC50s of 13.3 and 8.0 μM for DUSP6 and DUSP1, respectively.

In vitro activity:

BCI hydrochloride (BCI), a DUSP6 small molecule inhibitor, increased the activity of ERK but interestingly decreased the expression of ERK response genes in BGC823, SGC7901 and CDDP-resistant SGC7901/DDP cells. BCI also caused cell death through the DNA damage response (DDR) pathway. Moreover, BCI inhibited cell proliferation, migration and invasion in a receptor-independent manner and enhanced CDDP cytotoxicity at pharmacological concentrations in the gastric cancer (GC) cells. Reference: Cancer Lett. 2018 Jan 1;412:243-255. https://www.sciencedirect.com/science/article/pii/S0304383517306316?via%3Dihub

In vivo activity:

In vivo experiments showed that BCI enhances the antitumor effects of CDDP (cisplatin) in cell-based xenografts and PDX models. Reference: Cancer Lett. 2018 Jan 1;412:243-255. https://www.sciencedirect.com/science/article/pii/S0304383517306316?via%3Dihub

	Solvent	mg/mL	mM
Solubility
	DMF	2.0	5.65
	DMSO	12.8	36.20
	DMSO:PBS (pH 7.2) (1:1)	0.5	1.41

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 353.89 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Wu QN, Liao YF, Lu YX, Wang Y, Lu JH, Zeng ZL, Huang QT, Sheng H, Yun JP, Xie D, Ju HQ, Xu RH. Pharmacological inhibition of DUSP6 suppresses gastric cancer growth and metastasis and overcomes cisplatin resistance. Cancer Lett. 2018 Jan 1;412:243-255. doi: 10.1016/j.canlet.2017.10.007. Epub 2017 Oct 16. PMID: 29050982. 2. Zhang F, Tang B, Zhang Z, Xu D, Ma G. DUSP6 Inhibitor (E/Z)-BCI Hydrochloride Attenuates Lipopolysaccharide-Induced Inflammatory Responses in Murine Macrophage Cells via Activating the Nrf2 Signaling Axis and Inhibiting the NF-κB Pathway. Inflammation. 2019 Apr;42(2):672-681. doi: 10.1007/s10753-018-0924-2. PMID: 30506106.

In vitro protocol:

In vivo protocol:

1: Wu QN, Liao YF, Lu YX, Wang Y, Lu JH, Zeng ZL, Huang QT, Sheng H, Yun JP, Xie D, Ju HQ, Xu RH. Pharmacological inhibition of DUSP6 suppresses gastric cancer growth and metastasis and overcomes cisplatin resistance. Cancer Lett. 2018 Jan 1;412:243-255. doi: 10.1016/j.canlet.2017.10.007. Epub 2017 Oct 16. PubMed PMID: 29050982.